Testing Data
(Alemtuzumab bridging ELISA for pharmacokinetic (PK) assay developmentA microtiter plate was coated overnight with Human Anti-Alemtuzumab Antibody (clone AbD19189, HCA198) at a concentration of 1 mug/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of alemtuzumab (therapeutic reference product) or Human Anti-CD52 Antibody, MCA6101 (alemtuzumab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Alemtuzumab Antibody (clone AbD16942_hIgG1, HCA175P) at a concentration of 2 mug/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Human anti-Human CD52 Monoclonal Antibody | anti-CD52 antibody
Human Anti CD52 (Alemtuzumab Biosimilar)
Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Should this product contain a precipitate we recommend microcentrifugation before use.
Testing Data
(Alemtuzumab bridging ELISA for pharmacokinetic (PK) assay developmentA microtiter plate was coated overnight with Human Anti-Alemtuzumab Antibody (clone AbD19189, HCA198) at a concentration of 1 mug/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of alemtuzumab (therapeutic reference product) or Human Anti-CD52 Antibody, MCA6101 (alemtuzumab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Alemtuzumab Antibody (clone AbD16942_hIgG1, HCA175P) at a concentration of 2 mug/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Testing Data
(Alemtuzumab bridging ELISA for pharmacokinetic (PK) assay developmentA microtiter plate was coated overnight with Human Anti-Alemtuzumab Antibody (clone AbD19189, HCA198) at a concentration of 1 mug/ml. After washing and blocking with PBST + 5% BSA, 10% human serum was added spiked with increasing concentrations of alemtuzumab (therapeutic reference product) or Human Anti-CD52 Antibody, MCA6101 (alemtuzumab biosimilar, research grade). Detection was performed using HRP conjugated Human Anti-Alemtuzumab Antibody (clone AbD16942_hIgG1, HCA175P) at a concentration of 2 mug/ml in HISPEC Assay Diluent (BUF049A) and QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.)
Testing Data
(Purity assessment by SDS-PAGE0.5 mug of Human Anti-CD52 Antibody, MCA6101 (alemtuzumab biosimilar, research grade) and alemtuzumab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Testing Data
(Purity assessment by SDS-PAGE0.5 mug of Human Anti-CD52 Antibody, MCA6101 (alemtuzumab biosimilar, research grade) and alemtuzumab (therapeutic reference product) were denatured and analyzed under reducing (R) and non-reducing (NR) conditions. Bands were visualized using Coomassie staining. Full IgG (H2L2), heavy (H) and light chains (L) are indicated.)
Testing Data
(Monodispersity assessment by HPLC-SECSize exclusion chromatography (SEC) of Human Anti-CD52 Antibody, MCA6101 (alemtuzumab biosimilar, research grade) and alemtuzumab (therapeutic reference product) was performed on an analytical HPLC instrument. Shown are monomer peaks (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 mum; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 mul/min; inj. volume [mul]: 3; temp.: 25 degree C; detection: 280 nm; sample: mAb (1 mg/ml).)
Testing Data
(Monodispersity assessment by HPLC-SECSize exclusion chromatography (SEC) of Human Anti-CD52 Antibody, MCA6101 (alemtuzumab biosimilar, research grade) and alemtuzumab (therapeutic reference product) was performed on an analytical HPLC instrument. Shown are monomer peaks (H2L2), calculated relative monomer portion and aggregates. Column: MAbPac SEC-1, 5 mum; dimension: 4.0 x 150 mm; mobile phase: 50 mM sodium phosphate, pH 6.8, 300 mM NaCl, 200 mM Arginine; flow rate: 200 mul/min; inj. volume [mul]: 3; temp.: 25 degree C; detection: 280 nm; sample: mAb (1 mg/ml).)
Summary: Human Anti-CD52 Antibody, clone Campath-1H is a research grade biosimilar of the monoclonal antibody drug alemtuzumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic antibody Campath-1H.
Human Anti-CD52 Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-alemtuzumab antibodies, for example HCA198 and HCA175. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-alemtuzumab antibody in IgG1 format as reference standard, for example HCA175.
Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma. Alemtuzumab is also used in some conditioning regimes for bone marrow transplantation, kidney transplantation and islet cell transplantation along with clinical trial protocols for treatment of certain autoimmune diseases including multiple sclerosis.
NCBI and Uniprot Product Information
Uniprot Description
May play a role in carrying and orienting carbohydrate, as well as having a more specific role.
Research Articles on CD52
Similar Products
Product Notes
The CD52 cd52 (Catalog #AAA225702) is an Antibody produced from Human and is intended for research purposes only. The product is available for immediate purchase. The Human Anti CD52 (Alemtuzumab Biosimilar) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's CD52 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA). Researchers should empirically determine the suitability of the CD52 cd52 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CD52, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
